patent.fyi
Applications  /  US 2026/0355249
United States Patent Application Publication

US 2026/0355249 A1

Published
Nov 12, 2026
Filed
May 29, 2024
Earliest date on the face
Jun 1, 2023
Classification
A61K 35/28
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Culture in a hollow fiber cartridge

What ifWhat if a hollow fiber cartridge holds the culture medium and provides the cell attachment surface?
Claim language“on a plate”

A pump circulates medium through semipermeable fibers in a closed cartridge. Mesenchymal stem cells attach to the outer fiber surfaces and receive nutrients that diffuse across the fiber walls.

1.2Load cells onto porous ceramic

What ifWhat if a concentrated cell suspension is loaded directly onto a porous ceramic scaffold before culture medium is supplied?
Claim language“seeding MSCs in the standard culture medium”

A pipette dispenses cells suspended in isotonic buffered saline onto an absorbent calcium phosphate scaffold. Capillary flow draws the suspension into interconnected pores, and a perfusion chamber supplies growth medium after the cells attach.

1.3Combine cells from multiple aspirates

What ifWhat if multiple marrow aspirates from one donor supply the required cell count through recovery and pooling?
Claim language“to achieve their cell amplification”

Density separation concentrates nucleated cells from each aspirate, and immunomagnetic selection enriches a stromal cell fraction using surface markers. The recovered fractions are pooled and counted before conditioning.

1.4Condition with osteogenic supplements

What ifWhat if dexamethasone, ascorbate and beta-glycerophosphate provide the osteogenic stimulus?
Claim language“adding hyaluronic acid or a sulfated derivative thereof”

The supplements are dissolved in the basal medium before the medium is exchanged over the cells. Dexamethasone promotes osteogenic gene expression, ascorbate supports collagen deposition, and beta-glycerophosphate supplies phosphate for matrix mineralization.

1.4Bind hyaluronan to the substrate

What ifWhat if hyaluronic acid is tethered to the cell attachment surface and the liquid phase remains standard culture medium?
Claim language“to generate a conditioned medium”

Covalent coupling attaches hyaluronic acid to an amine-functionalized culture surface, and rinsing removes unbound polymer before cell loading. The immobilized polymer contacts cell-surface receptors while the basal medium supplies nutrients.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary screening for bone graft materials

Canine mesenchymal stromal cells expand in a multiwell plate and then incubate in medium supplemented with hyaluronic acid. The conditioned cells are transferred onto porous bone graft coupons held in separate wells. Parallel wells contain unconditioned cells on matching coupons, and the assay records cell attachment and alkaline phosphatase activity for each material.

Component substitution

Chondroitin sulfate as the conditioning additive

Mesenchymal stromal cells expand in basal culture medium in a tissue culture plate. Purified chondroitin sulfate replaces hyaluronic acid as the soluble conditioning additive and is mixed into fresh basal medium before the medium exchange. The cells incubate in the supplemented medium, and paired wells receiving basal medium alone serve as controls for alkaline phosphatase measurements.

Microcarrier suspension culture for cell expansion

A stirred culture vessel with collagen-coated microcarriers replaces the culture plate. Mesenchymal stromal cells attach to the microcarriers during intermittent mixing, then expand under continuous agitation that keeps the carriers suspended. After expansion, the carriers settle for medium exchange, and agitation resumes with hyaluronic acid-supplemented medium for the conditioning stage.

Parameter or scale variation

Timed conditioning in a multiwell plate

Mesenchymal stromal cells expand in a 24-well culture plate. After expansion, separate groups of wells receive the same hyaluronic acid formulation for 24, 72, or 96 hours. Each group has basal-medium controls harvested at the same time, and alkaline phosphatase activity is normalized to the DNA content of each well.

Combination with existing systems

Conditioned cells in a scaffold perfusion chamber

Mesenchymal stromal cells expand in plate culture and incubate in hyaluronic acid-supplemented medium before harvest. The conditioned cells are seeded onto a porous calcium phosphate scaffold that fits inside a gasketed flow chamber. After static attachment, a pump recirculates culture medium from a gas-exchanging reservoir through the scaffold, and the outlet returns medium to the reservoir.

Automated or data-driven variant

Image-triggered exchange of conditioning medium

A motorized microscope collects phase-contrast images at fixed positions in each culture well during mesenchymal stromal cell expansion. Image analysis calculates the fraction of each field covered by cells and compares the mean coverage per well with a preset threshold. When a well reaches that threshold, a liquid handler exchanges its basal medium for hyaluronic acid-supplemented medium and records the time for scheduled collection.

Specific version of a part

Prepare a buffered serum medium

A bicarbonate-buffered basal medium with glucose, amino acids and fetal bovine serum fills tissue culture-treated polystyrene wells. The plate equilibrates at 37 °C in a humidified atmosphere containing 5% carbon dioxide.

Seed a counted cell suspension

A viability count determines the volume of single-cell suspension needed for a seeding density of 4,000 viable cells per square centimeter. The suspension is dispensed into wells containing growth medium and distributed across each well by gentle rocking.

Expand cells in adherent monolayers

Cells proliferate on the treated plate surface at 37 °C, with growth medium replaced every two to three days. At approximately 80% confluence, an enzymatic dissociation solution releases the cells for viable counting and reseeding.

Mix soluble sodium hyaluronate

A sterile aqueous stock of sodium hyaluronate with a specified molecular weight is blended into the standard culture medium at a fixed dilution. Gentle mixing distributes the polymer throughout the liquid before the medium is dispensed onto the cells.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 10,226,481 B2
Published
Mar 12, 2019
Filed
Dec 16, 2016
Class
A61K 31/737
Document BUS 11,578,306 B2
Published
Feb 14, 2023
Filed
Sep 22, 2016
Class
C12N 5/06
Claim 1
Document A
Document B
1.1i—providing a standard culture medium suitable for the incubation of MSCs on a plate;
An exemplary incubation protocol comprised seeding cells on eight plates, where four plates were incubated with Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FCS and Fas-ligand at 50 ng/ml (Enzo life sciences) and four plates were incubated with DMEM supplemented with 10% FCS, as control.
B · US 11,578,306 B2 · ¶ 157
1.2ii—seeding MSCs in the standard culture medium;
An exemplary incubation protocol comprised seeding cells on eight plates, where four plates were incubated with Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% FCS and Fas-ligand at 50 ng/ml (Enzo life sciences) and four plates were incubated with DMEM supplemented with 10% FCS, as control.
B · US 11,578,306 B2 · ¶ 157
1.3iii—incubating the MSCs in the standard culture medium to achieve their cell amplification;
MSCs isolated from various tissues can be expanded in vitro while maintaining their potential to differentiate into specific cell lineages (4).
B · US 11,578,306 B2 · ¶ 21
1.4iv—adding hyaluronic acid or a sulfated derivative thereof to the standard culture medium to generate a conditioned medium; and
In one aspect, the hyaluronan starting material can be converted to low molecular hyaluronan or a hyaluronan oligosaccharide prior to sulfation to produce the partially sulfated hyaluronan.
A · US 10,226,481 B2 · ¶ 44
1.5v—incubating the MSCs in said conditioned medium.
SVF cells isolated from different lipoaspirates (the fatty portion) obtained from different donors were incubated at 37° C., 5% CO2 in a cell incubator in the presence of Fas-ligand under the conditions described below at several repeats.
B · US 11,578,306 B2 · ¶ 157

An empty cell means only that no passage was reproduced there.

Statements in these documents
Presently, the treatment of this condition has been suboptimal because of its uncertain cause and pathogenesis.
A · US 10,226,481 B2 · ¶ 3
A fundamental lack of understanding of the inflammatory cascades that perpetuate the disease process has resulted in a paucity of therapeutic options.
A · US 10,226,481 B2 · ¶ 3
Therefore, establishment of protocols for MSCs isolation and expansion is desirable for obtaining an enriched cell population for further clinical use.
B · US 11,578,306 B2 · ¶ 21
MSCs isolated from various tissues can be expanded in vitro while maintaining their potential to differentiate into specific cell lineages (4).
B · US 11,578,306 B2 · ¶ 21
Cite aspatent.fyi, US 2026/0355249 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355249/, SHA-256 8ae72b1324aa2495c0b74c0cac05b1f543a38ce9171e390595690ae8e13eb1dc
First published
Permanent addresshttps://patent.fyi/US20260355249/
Content fingerprint (SHA-256)8ae72b1324aa2495c0b74c0cac05b1f543a38ce9171e390595690ae8e13eb1dc
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi